How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about solriamfetol

Marketing authorisation indication

2.1 Solriamfetol (Sunosi, Jazz Pharmaceuticals) has a marketing authorisation to improve wakefulness and reduce excessive daytime sleepiness in adult patients with obstructive sleep apnoea whose excessive daytime sleepiness has not been satisfactorily treated by primary obstructive sleep apnoea therapy such as continuous positive airway pressure (CPAP).

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price for solriamfetol is £177.52 for a 75‑mg 28‑day pack and £248.64 for a 150‑mg 28‑day pack (BNF online accessed February 2021). Costs may vary in different settings because of negotiated procurement discounts.